235 related articles for article (PubMed ID: 29607978)
1. The Efficacy of Minodronate in the Treatment of Glucocorticoid-induced Osteoporosis.
Hasegawa E; Ito S; Takai C; Kobayashi D; Nomura Y; Otani H; Abe A; Ishikawa H; Murasawa A; Narita I; Nakazono K
Intern Med; 2018 Aug; 57(15):2169-2178. PubMed ID: 29607978
[TBL] [Abstract][Full Text] [Related]
2. Patient satisfaction and efficacy of switching from weekly bisphosphonates to monthly minodronate for treatment and prevention of glucocorticoid-induced osteoporosis in Japanese patients with systemic rheumatic diseases: a randomized, clinical trial.
Tamechika SY; Sasaki K; Hayami Y; Ohmura SI; Maeda S; Iwagaitsu S; Naniwa T
Arch Osteoporos; 2018 Jun; 13(1):67. PubMed ID: 29904824
[TBL] [Abstract][Full Text] [Related]
3. Effect of osteoporosis medication on changes in bone mineral density and bone turnover markers after 24-month administration of daily teriparatide: comparison among minodronate, raloxifene, and eldecalcitol.
Nakatoh S
J Bone Miner Metab; 2018 Mar; 36(2):221-228. PubMed ID: 28293779
[TBL] [Abstract][Full Text] [Related]
4. Minodronate combined with alfacalcidol versus alfacalcidol alone for glucocorticoid-induced osteoporosis: a multicenter, randomized, comparative study.
Soen S; Yamamoto K; Takeuchi T; Tanaka Y; Tanaka S; Ito M; Nakano T; Hagino H; Hirakawa A; Matsumoto T
J Bone Miner Metab; 2020 Jul; 38(4):511-521. PubMed ID: 31970477
[TBL] [Abstract][Full Text] [Related]
5. Effects of once-monthly minodronate versus risedronate in osteoporosis patients with rheumatoid arthritis: a 12-month randomized head-to-head comparison.
Kumagai K; Harigane K; Kusayama Y; Tezuka T; Choe H; Inaba Y; Saito T
Osteoporos Int; 2018 Jul; 29(7):1637-1642. PubMed ID: 29574518
[TBL] [Abstract][Full Text] [Related]
6. Minodronate in the treatment of osteoporosis: A systematic review and meta-analysis.
Liu Q; Chen D; Ye Z; Jin Z; Ma T; Huang X
Medicine (Baltimore); 2020 Oct; 99(40):e22542. PubMed ID: 33019463
[TBL] [Abstract][Full Text] [Related]
7. Minodronate for the treatment of osteoporosis.
Kubo T; Shimose S; Matsuo T; Fujimori J; Ochi M
Drugs Today (Barc); 2010 Jan; 46(1):33-7. PubMed ID: 20200694
[TBL] [Abstract][Full Text] [Related]
8. Significant improvement of bone mineral density by denosumab without bisphosphonate pre-treatment in glucocorticoid-induced osteoporosis.
Suzuki T; Nakamura Y; Kato H
Mod Rheumatol; 2018 Sep; 28(5):885-889. PubMed ID: 29251033
[TBL] [Abstract][Full Text] [Related]
9. Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study.
Matsumoto T; Hagino H; Shiraki M; Fukunaga M; Nakano T; Takaoka K; Morii H; Ohashi Y; Nakamura T
Osteoporos Int; 2009 Aug; 20(8):1429-37. PubMed ID: 19101754
[TBL] [Abstract][Full Text] [Related]
10. Serum homocysteine levels are affected by renal function during a 3-year period of minodronate therapy in female osteoporotic patients.
Ohishi T; Fujita T; Suzuki D; Nishida T; Asukai M; Matsuyama Y
J Bone Miner Metab; 2019 Mar; 37(2):319-326. PubMed ID: 29603071
[TBL] [Abstract][Full Text] [Related]
11. Initiation of Monthly Minodronate Therapy at an Early Stage After Hip Fracture.
Ohishi T; Fujita T; Suzuki D; Nishida T; Okabayashi R; Yamamoto K; Ushirozako H; Banno T; Matsuyama Y
J Clin Densitom; 2016; 19(3):352-8. PubMed ID: 27067298
[TBL] [Abstract][Full Text] [Related]
12. Effects of switching weekly alendronate or risedronate to monthly minodronate in patients with rheumatoid arthritis: a 12-month prospective study.
Ebina K; Noguchi T; Hirao M; Hashimoto J; Kaneshiro S; Yukioka M; Yoshikawa H
Osteoporos Int; 2016 Jan; 27(1):351-9. PubMed ID: 26475289
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy and treatment persistence of monthly minodronate for osteoporotic patients unsatisfied with, and shifted from, daily or weekly bisphosphonates: the BP-MUSASHI study.
Sakai A; Ikeda S; Okimoto N; Matsumoto H; Teshima K; Okazaki Y; Fukuda F; Arita S; Tsurukami H; Nagashima M; Yoshioka T
Osteoporos Int; 2014 Sep; 25(9):2245-53. PubMed ID: 24899103
[TBL] [Abstract][Full Text] [Related]
14. Denosumab is effective toward glucocorticoid-induced osteoporosis patients complicated with rheumatic diseases regardless of prior anti-osteoporotic drugs.
Iwamoto N; Okamoto M; Tsuji S; Endo Y; Takatani A; Shimizu T; Umeda M; Fukui S; Sumiyoshi R; Igawa T; Koga T; Kawashiri SY; Aramaki T; Ichinose K; Tamai M; Nakamura H; Origuchi T; Eguchi K; Ueki Y; Kawakami A
J Bone Miner Metab; 2019 May; 37(3):554-562. PubMed ID: 30187273
[TBL] [Abstract][Full Text] [Related]
15. Modeling and simulation of bone mineral density in Japanese osteoporosis patients treated with zoledronic acid using tartrate-resistant acid phosphatase 5b, a bone resorption marker.
Mori Y; Kasai H; Ose A; Serada M; Ishiguro M; Shiraki M; Tanigawara Y
Osteoporos Int; 2018 May; 29(5):1155-1163. PubMed ID: 29423715
[TBL] [Abstract][Full Text] [Related]
16. Teriparatide or alendronate in glucocorticoid-induced osteoporosis.
Saag KG; Shane E; Boonen S; Marín F; Donley DW; Taylor KA; Dalsky GP; Marcus R
N Engl J Med; 2007 Nov; 357(20):2028-39. PubMed ID: 18003959
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of discontinuing risedronate for patients with systemic lupus erythematosus: a prospective study.
Ishida T; Yoshida S; Kimura Y; Fujiki Y; Kotani T; Takeuchi T; Makino S; Arawaka S
Lupus; 2018 Sep; 27(10):1636-1643. PubMed ID: 29954283
[TBL] [Abstract][Full Text] [Related]
18. Further significant effects of eldecalcitol on bone resorption markers and bone mineral density in postmenopausal osteoporosis patients having undergone long-term bisphosphonate treatment.
Iba K; Sonoda T; Takada J; Dohke T; Yamashita T
J Bone Miner Metab; 2017 Mar; 35(2):171-176. PubMed ID: 26832388
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of monthly oral minodronate in patients with involutional osteoporosis.
Okazaki R; Hagino H; Ito M; Sone T; Nakamura T; Mizunuma H; Fukunaga M; Shiraki M; Nishizawa Y; Ohashi Y; Matsumoto T
Osteoporos Int; 2012 Jun; 23(6):1737-45. PubMed ID: 21932114
[TBL] [Abstract][Full Text] [Related]
20. Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids.
Devogelaer JP; Sambrook P; Reid DM; Goemaere S; Ish-Shalom S; Collette J; Su G; Bucci-Rechtweg C; Papanastasiou P; Reginster JY
Rheumatology (Oxford); 2013 Jun; 52(6):1058-69. PubMed ID: 23365149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
